An interim injunction from the Delhi High Court paused Zydus Lifesciences’ bid to launch the biosimilars of Roche’s breast cancer drug Perjeta (pertuzumab). But as the story unfolds, experts from multinational companies raised objections around the transparency in the clinical trial process. They also alleged the due process for the biosimilar’s approvals was not followed. Experts from the Indian industry steadfastly refuted Roche’s claims., An interim injunction from the Delhi High Court paused Zydus Lifesciences’ bid to launch the biosimilars of Roche’s breast cancer drug Perjeta (pertuzumab). But as the story unfolds, experts from multinational companies raised objections around the transparency in the clinical trial process. They also alleged the due process for the biosimilar’s approvals was not followed. Experts from the Indian industry steadfastly refuted Roche’s claims., , Read More
AAS Yoga
Go for Euphoria – Illness to Wellness the Natural Way